🟥 Member Event : 2026 Linda Gammage Social Workers CE Conference
2026-02-25 18:30 - 2026-02-27 15:30 (America/New_York)
Date: February 25 – 27, 2026
Location: Oklahoma City, OK

Please contact Theresa Parker with any questions regarding this registration at theresa@hemoalliance.org or 727-688-2568.

🟦 Non-Member Event : NBDF Washington Days
2026-03-04 - 2026-03-06
Date: March 4 – 6 (Washington, D.C.)
Click here for info.

🟥 Member Webinar : Hemophilia Alliance Hosts - A Webinar from Takeda - Overview of Patient Tools & Support Resources
2026-03-05 13:00 - 14:00 (America/New_York)
Date: Thursday, March 5th, 2026
Time: 1:00pm – 2:00pm ET

WEBINAR TOPIC:
Overview of Patient Tools & Support Resources.
OBJECTIVE:
This presentation will provide an overview of Takeda Hematology Patient tools and Support resources and education on the navigation of these tools and resources.
AUDIENCE:
All HTC Staff.
SPEAKERS:
Carley Riehle – Specialty Pharmacy National Account Director, HEM Alliance Account Lead

Katrina McGrath – Community Education Lead for US HEM Franchise

Nicole Loguidice – Associate Director for Hematology Patient Access Operations

Erik Evans – Regional Director for Rare Diseases/PDT Patient Access – Field

🟥 Member Event : 2026 Spring Members Meeting
2026-03-08 18:30 - 2026-03-10 15:30 (America/New_York)
Date: March 8 – 10, 2026
Location: Seattle, WA

Please contact Theresa Parker with any questions regarding this registration at theresa@hemoalliance.org or 727-688-2568.

🟥 Member Webinar : Hemophilia Alliance Hosts - A Webinar from Takeda - Inhibitor Development in Hemophilia A: A Continuing Clinical Challenge Despite Therapeutic Advances
2026-03-12 13:00 - 14:00 (America/New_York)
Date: Thursday, March 12th, 2026
Time: 1:00pm – 2:00pm ET

WEBINAR TOPIC:
Inhibitor Development in Hemophilia A: A Continuing Clinical Challenge Despite Therapeutic Advances.
OBJECTIVE:
After this webinar, participants will be able to:

Describe the clinical impact and risk factors for FVIII inhibitor development in Previously Untreated Patients (PUPs)
Summarize key findings from past PUP studies, including the SIPPET trial
Review Phase 3 PUP trial data for rurioctocog alfa pegol
Discuss implications for monitoring and managing inhibitor risk in current clinical practice

AUDIENCE:
All HTC Staff.
SPEAKERS:

Caitlin Montcrieff, MSN, CPNP – Director, US Medical Hematology & Rare Disease

Robert Sidonio, MD, MSc
Dr. Robert F. Sidonio, Jr, MD, MSc is a Professor of pediatrics at Emory University School of Medicine and the Medical Director of the Hemophilia of Georgia Pediatric Center for Bleeding and Clotting Disorders of Emory. Dr. Sidonio’s clinical and research interests are in the management of pediatric patients with bleeding disorders. His research focus has included women with bleeding disorders, von willebrand disease and the study of inhibitor development in patients with Hemophilia A. Dr. Sidonio was the principal investigator for the Phase 3 clinial trial of rurioctocog alfa pegol in previously untreated patients with Hemophilia A.

🟦 Non-Member Event : THSNA 2026 Thrombosis & Hemostasis Summit of North America
2026-03-19 - 2026-03-21
Date: March 19 – 21 (Portland, OR)
Click here for info.

🟥 Member Webinar : Hemophilia Alliance Hosts - A Webinar from BrightStar Care - BrightStar Franchising Nursing Care Agreement
2026-03-31 13:00 - 14:00 (America/New_York)
Date: Tuesday, March 31st, 2026
Time: 1:00pm – 2:00pm ET

WEBINAR TOPIC:
BrightStar Franchising, LLC Master Service Agreement for Nursing Services Now Available to Hemophilia Alliance Member Hemophilia Treatment Centers.
OBJECTIVES:

Understand the services of BrightStar Franchising, LLC. And what services are available to Hemophilia Alliance member HTCs under the Master Service Agreement

Who is BrightStar Franchising, LLC
What services are available through this Master Services Agreement to Hemophilia Treatment Centers (HTC)
What states are BrightStar Franchises located/not located
How do HTCs access the BrightStar local agencies for services

Review of the key aspects of the Master Service Agreement

Key considerations for HTCs
Key considerations for BrightStar Franchises

AUDIENCE:
All HTC Staff.
SPEAKERS:

Wil Cabrera, MBA
VP, National Accounts

Debra Smith, MBA HCM
Sr. Director, Centralized Intake Operations

Joshua Allen, RN
Sr. Director Infusion Services

🟦 Non-Member Event : The Coalition for Hemophilia B 2026 Annual Symposium
2026-04-09 - 2026-04-12
Date: April 9 – 12 (Las Vegas, NV)
Click here for info.

🟦 Non-Member Event : HFA 2026 Symposium
2026-04-16 - 2026-04-19
Date: April 16 – 19 (New Orleans, LA)
Click here for info.

🟦 Non-Member Event : WFH 2026 World Congress
2026-04-19 - 2026-04-22
Date: April 19 – 22 (Malaysia)
Click here for info.

🟥 Member Event : 2026 New HTC Staff Meeting
2026-04-21 18:30 - 2026-04-23 15:30 (America/New_York)
Date: April 21 – 23, 2026
Location: Aurora, CO

Please contact Theresa Parker with any questions regarding this registration at theresa@hemoalliance.org or 727-688-2568.

🟥 Member Webinar : Hemophilia Alliance Hosts - A Webinar from Sanofi - Targeted Multi-Immune Modulation in ITP
2026-04-28 16:30 - 17:30 (America/New_York)
Date: Tuesday, April 28th, 2026
Time: 4:30pm – 5:30pm ET

WEBINAR TOPIC:
Targeted Multi-Immune Modulation in ITP
DESCRIPTION:
This event will provide an overview of a multi-immune modulator that helps address the complex immune dysregulation in immune thrombocytopenia (ITP). The presentation will highlight key aspects of the disease pathophysiology, the potential benefits of a multi-immune modulator and clinical trial evidence in ITP patients.
AUDIENCE:
All HTC Staff.
SPEAKER:

Michael Tarantino, MD
Dr. Tarantino has more than 30 years of experience in hematology, as well as 14 years of experience as the Founder, Chief Medical Officer and Chief Executive Officer of the Bleeding & Clotting Disorders Institute. For over three decades he has devoted his medical career to the management of bleeding and blood clotting disorders, as well as non-malignant hematology disorders.
Dr. Tarantino also serves as the Medical Director of the Anticoagulation Consultation Service at St. Francis Medical Center. Since 2008, Dr. Tarantino is a tenured Professor of Pediatrics and Medicine at the University of Illinois College of Medicine in Peoria and is active in teaching medical students, residents and allied health professionals.
Dr. Tarantino earned a Doctor of Medicine degree from the University of Wisconsin School of Medicine and Public Health in 1987. He then completed a residency in pediatrics from the University of Arizona in 1990 and a fellowship in pediatric hematology and oncology from the University of Wisconsin in 1993.
Dr. Tarantino is board certified in Pediatric Hematology and Oncology. He is the chairman of the Medical Advisory Board of the Platelet Disorder Support Association and served as a member of the Medical Advisory and Scientific Council of the National Bleeding Disorders Foundation from 2012-2022. In 2005 and 2017 Dr. Tarantino received the Research Excellence Award from the University of Illinois College of Medicine, and in 2012 and 2018 he was awarded the Physician of the Year and the Excellence in Healthcare Award, respectively, from the National Bleeding Disorders Foundation. In 2024, Dr. Tarantino was honored to receive a Lifetime Achievement Award from NBDF for his dedicated career of improving the lives of individuals with bleeding disorders- helping them live longer lives while empowering them to become their own advocates.
Dr. Tarantino has had an active career in clinical and translational research. As a result, he has authored or co-authored over 125 peer-reviewed papers, reviews and book chapters, in addition to over 140 scientific abstracts.

🟥 Member Event : 2026 Nurses CE Meeting
2026-05-03 18:30 - 2026-05-05 15:30 (America/New_York)
Date: May 3 – 5, 2026
Location: Chicago, IL

Please note: this application button will redirect you to Cvent, the Alliance’s NEW management registration platform.

Please contact Theresa Parker with any questions regarding this registration at theresa@hemoalliance.org or 727-688-2568.

🟥 Member Event : 2026 Physical Therapists CE Meeting
2026-05-06 18:30 - 2026-05-08 15:30 (America/New_York)
Date: May 6 – 8, 2026
Location: Chicago, IL

Please note: this application button will redirect you to Cvent, the Alliance’s NEW management registration platform.

Please contact Theresa Parker with any questions regarding this registration at theresa@hemoalliance.org or 727-688-2568.

🟥 Member Webinar : Hemophilia Alliance Hosts - A Webinar from Octapharma - Addressing Heavy Menstrual Bleeding in von Willebrand Disease: Clinical Insights and the Role of wilate®
2026-05-12 13:00 - 14:00 (America/New_York)
Date: Tuesday, May 12th, 2026
Time: 1:00pm – 2:00pm ET

WEBINAR TOPIC:
Addressing Heavy Menstrual Bleeding in von Willebrand Disease: Clinical Insights and the Role of wilate®
OBJECTIVES:

Heavy menstrual bleeding (HMB) is one of the most common and underrecognized manifestations of von Willebrand disease (VWD) and represents a significant cause of iron deficiency and iron deficiency anemia in affected women. Chronic blood loss associated with HMB can lead to fatigue, impaired cognitive and physical functioning, reduced quality of life, and increased healthcare utilization. Despite its prevalence, both VWD and iron deficiency related to HMB are frequently underdiagnosed and undertreated.
This webinar will provide a focused clinical overview of HMB in the context of VWD, emphasizing the interconnected relationship between abnormal bleeding and iron deficiency. Participants will review the burden of disease, diagnostic considerations, and treatment goals aimed at controlling bleeding while addressing its systemic consequences. The program will also highlight Wilate®, a VWF/FVIII concentrate, including its clinical profile, supporting evidence, and practical application in the management of HMB associated with VWD. Finally, the webinar will explore Wilate’s clinical and therapeutic value proposition, with an emphasis on optimizing outcomes and improving quality of life for women living with VWD-related HMB.

AUDIENCE:
All HTC Staff.
SPEAKER:

Claudio Sandoval, MD – Senior Director, Scientific and Medical Affairs – Hematology Octapharma USA
Claudio Sandoval is the Director of Scientific & Medical Affairs at Octapharma. Before his current role he was a pediatric hematologist-oncologist for 30 years caring for children with bleeding disorders, cancer, sickle cell disease, and other maladies. Claudio graduated from New York Medical College and trained at Schneider Children’s Hospital in New Hyde Park, NY and St. Jude Children’s Research Hospital in Memphis, TN.

🟦 Non-Member Event : 340B Grantee Spring Conference
2026-05-28 - 2026-05-30
Date: May 28 – 30 (Houston, TX)
Click here for info.

🟦 Non-Member Event : 340B Coalition Summer Conference
2026-07-13 - 2026-07-15
Date: July 13 – 15 (Washington, D.C.)
Click here for info.

🟥 Member Webinar : Hemophilia Alliance Hosts - An Update on Takeda’s Transformation, Supply Status, and Hemophilia A Treatments
2026-07-22 13:00 - 14:00 (America/New_York)
Date: Wednesday, July 22nd, 2026
Time: 1:00pm – 2:00pm ET

WEBINAR TOPIC:
An Update on Takeda’s Transformation, Supply Status, and Hemophilia A Treatments
OBJECTIVES:

To familiarize audiences with Takeda transformation update
To share reminder on the HEMOFIL® M & RECOMBINATE® supply status
To share HCP presentation focusing on the immunogenicity results of the ADYNOVATE phase 3 trial in previously untreated patients (PUPs) and attributes of ADVATE for previously treated patients (PTPs).

AUDIENCE:
All HTC Staff
SPEAKERS:
Dr. Jonathan Roberts is the Associate Medical Director and Associate Research Director at the Bleeding and Clotting Disorders Institute in Peoria, IL. He also serves as an Associate Professor of Pediatrics and Medicine at the University of Illinois College of Medicine in Peoria, IL.
Dr. Roberts’ research focuses on developing novel laboratory assays to improve the diagnosis of von Willebrand Disease (VWD) and enhancing individualized clinical management of hemophilia, VWD, and other rare bleeding disorders. He has received numerous young investigator research awards and has authored over 100 peer-reviewed research publications and abstracts. His work includes lead and senior author publications in prominent journals such as Blood, the Journal of Thrombosis and Haemostasias, and the New England Journal of Medicine. He has also secured grant funding from organizations such as the National Bleeding Disorders Foundation, the World Federation of Hemophilia, and the National Institutes of Health.

Carley Riehle has been with Takeda for nearly nine years and has built her career around supporting the bleeding disorder community. She began in the field, calling on HTCs, hospitals, and chapters before leading a team of field members, where she developed a deep appreciation for the strength and resilience of the community. She later transitioned to Takeda’s Payer Team, where she focused on creating and protecting access for patients on Takeda therapies. Most recently, Carley was promoted to National Director of Specialty Pharmacy, where she partners with national specialty pharmacies and the Hemophilia Alliance to strengthen Takeda’s relationships, support their members, and ultimately improve access for patients. She is passionate about building trusted partnerships and advancing meaningful support for the bleeding disorder community.

Natalie Wu, Head of Takeda’s US Hematology and Transplant Franchise is biopharmaceutical leader with over 25 years of diverse US and Global experience across Rare Diseases, Oncology, Diabetes, and Neuroscience. Natalie is passionate about building deep connections with the patient communities we serve and the healthcare and advocacy teams who work tirelessly to support patients in their quest for better health. She challenges the status quo to drive meaningful impact where unmet needs and heath inequities remain.

Nicole Loguidice, MBA is Director, Foundational Therapeutics Platform Access Operations at Takeda. With more than eight years of experience in patient access, she has led operations across Hematology, Rare Disease, Endocrinology, and Transplant programs. Nicole is passionate about developing patient-centered access solutions, fostering cross-functional collaboration, and advancing programs that support patients’ access to the therapies they need.

🟥 Member Webinar : Hemophilia Alliance Presents - A Webinar on Planning for Medicaid Work Requirements
2026-07-30 14:00 - 15:00 (America/New_York)

🟦 Non-Member Event : NBDF BDC
2026-08-13 - 2026-08-15
Date: August 13 – 15 (Orlando, FL)
Click here for info.

🟥 Member Webinar : New HANS PBM Agreement Opportunities
2026-08-26 13:00 - 14:00 (America/New_York)

🟥 Member Event : 2026 Fall Members Meeting & Hill Day
2026-09-27 18:30 - 2026-09-29 17:30 (America/New_York)
Date: September 27 – 29, 2026
Location: Washington, DC
Please note: this button will redirect you to Cvent, the Alliance’s NEW management registration platform.

Please contact Theresa Parker with any questions regarding this registration at theresa@hemoalliance.org or 727-688-2568.

🟦 Non-Member Event : FWGBD Annual Conference
2026-10-09 - 2026-10-11
Date: October 9 – 11 (Boston, MA)
Click here for info.

🟦 Non-Member Event : ATHN Data Summit
2026-10-21 - 2026-10-22
Date: October 21 – 22, 2026 (New Orleans, LA)
Click here for info.

🟦 Non-Member Event : ASH Annual Meeting & Exposition
2026-12-12 - 2026-12-15
Date: December 12 – 15 (New Orleans, LA)
Click here for info.

🟥 Member Event : 2027 MPBA Meeting
2027-01-24 18:30 - 2027-01-26 14:00 (America/Phoenix)
Date: January 24 – 26, 2027
Location: Salt Lake City, UT
Please note: this button will redirect you to Cvent, the Alliance’s NEW management registration platform.

Please contact Theresa Parker with any questions regarding this registration at theresa@hemoalliance.org or 727-688-2568.
